180 related articles for article (PubMed ID: 27628551)
1. [A Case of Luminal-HER2 Advanced Breast Cancer with Liver Metastasis Showed Pathological Complete Response to the Therapy with Pertuzumab plus Trastuzumab plus Docetaxel].
Hamaoka A; Matsuda T; Konishi E; Taguchi T
Gan To Kagaku Ryoho; 2016 Sep; 43(9):1097-100. PubMed ID: 27628551
[TBL] [Abstract][Full Text] [Related]
2. [A Case of Locally-Advanced Breast Cancer with Liver Metastasis, Treated with Mastectomy of the Primary Tumor after Chemotherapy].
Kanada Y; Matsuzaki H; Kobayashi H; Suzuki K; Sawada H; Senba Y; Yoshioka T; Note H; Sato Y; Miyazaki A; Natsume T; Tanaka H; Maruyama T
Gan To Kagaku Ryoho; 2015 Nov; 42(12):1509-11. PubMed ID: 26805079
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
4. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].
Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029
[TBL] [Abstract][Full Text] [Related]
5. [A case of effective trastuzumab plus gemcitabine therapy for human epidermal growth factor receptor 2-positive breast cancer].
Yabe N; Murai S; Shimizu H; Kitasato K; Yoshikawa T; Oto I; Nakadai J; Jinno H; Kitagawa Y
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2396-8. PubMed ID: 24394124
[TBL] [Abstract][Full Text] [Related]
6. A Locally Advanced Breast Cancer that Achieved pCR with Pertuzumab, Trastuzumab and Docetaxel: Case Report.
Inoue Y; Yamashita N; Tokunaga E; Tanaka K; Ueo H; Saeki H; Oki E; Yamamoto H; Maehara Y
Anticancer Res; 2017 Apr; 37(4):1917-1921. PubMed ID: 28373460
[TBL] [Abstract][Full Text] [Related]
7. Case records of the Massachusetts General Hospital. Case 16-2012. A 32-year-old woman with HER2-positive breast cancer.
Baselga J; Smith BL; Rafferty EA; Bombonati A
N Engl J Med; 2012 May; 366(21):2018-26. PubMed ID: 22621630
[No Abstract] [Full Text] [Related]
8. [A case of HER2-positive breast cancer for which preoperative chemotherapy with pertuzumab resulted in a pathological complete response].
Abe H; Yamazaki K; Yoneda K; Ogawa M; Kawasaki M; Yoneda G; Yoshimura M; Kameyama M
Gan To Kagaku Ryoho; 2015 Apr; 42(4):485-8. PubMed ID: 25963698
[TBL] [Abstract][Full Text] [Related]
9. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.
Glück S; Ross JS; Royce M; McKenna EF; Perou CM; Avisar E; Wu L
Breast Cancer Res Treat; 2012 Apr; 132(3):781-91. PubMed ID: 21373875
[TBL] [Abstract][Full Text] [Related]
10. A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel.
Kunitomo K; Inoue S; Ichihara F; Kono K; Fujii H; Matsumoto Y; Ooi A
Hum Pathol; 2004 Mar; 35(3):379-81. PubMed ID: 15017597
[TBL] [Abstract][Full Text] [Related]
11. Sentinel lymph node biopsy in patients with operable breast cancer treated with neoadjuvant chemotherapy.
Rebollo-Aguirre AC; Gallego-Peinado M; Menjón-Beltrán S; García-García J; Pastor-Pons E; Chamorro-Santos CE; Ramos-Font C; Salamanca-Ballesteros A; Llamas-Elvira JM; Olea-Serrano N
Rev Esp Med Nucl Imagen Mol; 2012; 31(3):117-23. PubMed ID: 21676504
[TBL] [Abstract][Full Text] [Related]
12. [A Case of HER2-Positive Breast Cancer with Newly Diagnosed Stage IV That Responded to First-Line Pertuzumab and Trastuzumab-Based Therapy].
Yoshioka S; Hojo S; Toyoda Y; Maeura Y
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1214-1216. PubMed ID: 29394585
[TBL] [Abstract][Full Text] [Related]
13. [A Case of HER2-Positive Breast Cancer with Liver Metastases Showing Three Years of Complete Response to Combination Therapy with Trastuzumabplus Pertuzumab].
Fujimoto Y; Yamaguchi K; Ueno A; Sakurai R; Nagahisa Y; Imai S; Kawamoto K
Gan To Kagaku Ryoho; 2018 Mar; 45(3):459-461. PubMed ID: 29650905
[TBL] [Abstract][Full Text] [Related]
14. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and toxicity of trastuzumab combined with docetaxel for Her-2/neu overexpressing metastatic breast cancer].
Zhou NN; Lin XB; Liu DG; Teng XY; Zhong JT; Jiang WQ
Ai Zheng; 2008 Sep; 27(9):947-50. PubMed ID: 18799033
[TBL] [Abstract][Full Text] [Related]
16. [A Case of HER2-Positive Breast Cancer Treated with Nipple-Sparing Mastectomywith Immediate Reconstruction Using a Tissue Expander after Nab-Paclitaxel Combined with Chemotherapy].
Nonomura A; Aomatsu N; Tei S; Haraoka G; Tsujio G; Yamakoshi Y; Wang E; Nagashima D; Hirakawa T; Iwauchi T; Nishii T; Morimoto J; Nakazawa K; Uchima Y; Takeuchi K
Gan To Kagaku Ryoho; 2016 Nov; 43(12):2056-2058. PubMed ID: 28133220
[TBL] [Abstract][Full Text] [Related]
17. [A case of effective combination therapy with docetaxel, cyclophosphamide and trastuzumab as primary systemic therapy for locally advanced HER2-positive breast cancer].
Mizuta N; Nishiyama A; Mizuta M; Goto M; Imai A; Umeda Y; Morita M; Sakaguchi K; Konishi E; Taguchi T
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1491-4. PubMed ID: 21918347
[TBL] [Abstract][Full Text] [Related]
18. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
Kawajiri H; Takashima T; Kashiwagi S; Noda S; Onoda N; Hirakawa K
Expert Rev Anticancer Ther; 2015 Jan; 15(1):17-26. PubMed ID: 25494663
[TBL] [Abstract][Full Text] [Related]
19. [HER2-Positive Breast Cancer with Severe Infusion Reaction to Pertuzumab plus Trastuzumab-A Case Report].
Matsuoka A; Inoue H; Ogura K; Hattori A; Yukawa H; Sakaguchi S; Tanaka N; Kodera A; Kamimura M; Naritaka Y; Hirano A
Gan To Kagaku Ryoho; 2018 Dec; 45(13):1863-1865. PubMed ID: 30692379
[TBL] [Abstract][Full Text] [Related]
20. Pertuzumab, trastuzumab and docetaxel reduced the recurrence of brain metastasis from breast cancer: a case report.
Senda N; Yamaguchi A; Nishimura H; Shiozaki T; Tsuyuki S
Breast Cancer; 2016 Mar; 23(2):323-8. PubMed ID: 26116144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
